Using SCLC cell lines, we demonstrated susceptibility to killing by our putative CCT inhibitor, CT20p, which proved more effective than a STAT3 inhibitor, and the resulting reduction of CCT client proteins (e.g., STAT3) in part addressed the mechanism of action for CT20p. This evidence concerns the gene FLVCR2 and small cell lung carcinoma.